<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47458">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02488382</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-14-1852-AN-CTIL</org_study_id>
    <nct_id>NCT02488382</nct_id>
  </id_info>
  <brief_title>Lonquek for Autologous Stem Cell Mobilization</brief_title>
  <official_title>Lonquek (Lipegfilgrastim) for Stem Cell Mobilization of Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy and tolerability of Lonquek which is a
      pegylated (long-acting) version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing
      sufficient number of stem cells for autologous stem cell transplantation in patients with
      lymphoma and multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mobilisation success rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mobilisation success rate is defined as the mobilisation of a peripheral blood stem cell graft containing &gt;2x106 CD34+ cells/kg in â‰¤ 4 apheresis sessions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>engraftment after transplantation</measure>
    <time_frame>100 days</time_frame>
    <description>Time until recovery of blood counts after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>100 days</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lonquek</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with Lonquek for autologous stem cell collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lonquek</intervention_name>
    <description>Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.</description>
    <arm_group_label>Lonquek</arm_group_label>
    <other_name>Lipegfilgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed multiple myeloma or Hodgkins or non Hodgkin lymphoma at need
             of autologous stem cell transplantation.

          -  Disease must be chemosensitive or stable status to prior therapy before transplant.

          -  Age between 18 and 65 years inclusive.

          -  ECOG performance status 0, 1 or 2.

          -  Written informed consent.

          -  Adequate birth control in fertile patients.

        Exclusion Criteria:

          -  Lymphoma patients that did not fulfill the inclusion criteria.

          -  Patients with factors predicting poor mobilization including &gt;3 lines of previous
             chemotherapy, extensive irradiation, patients that received stem cell toxicity drugs
             like Melphalan, Fludarabine, &gt;2 courses of Revlimid, age &gt;65 years, platelets counts
             &lt;100x109/L, WBC&lt;2.5x109/L or WBC &gt; 35x109/L.

          -  Previous autologous stem cell transplantation.

          -  Inability to tolerate peripheral blood stem cell harvest.

          -  Peripheral venous access not possible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnon Nagler, MD</last_name>
    <phone>972 3 530 5830</phone>
    <email>a.nagler@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Avichai Shimoni, MD</last_name>
    <phone>9972 3 530 5830</phone>
    <email>ashimoni@sheba.health.gov.il</email>
  </overall_contact_backup>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 19, 2016</lastchanged_date>
  <firstreceived_date>May 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>stem cell mobilization</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
